explore microsampling applications in TDM at IATDMCT 2018 in australia
Attendees at the 16th Annual Congress of Therapeutic Drug Monitoring and Clinical Toxicology (IADTMCT 2018) in Brisbane, Australia will have a rare opportunity to get a close-up, in-depth look at groundbreaking applications for Mitra® microsampling devices and Volumetric Absorptive Microsampling (VAMS™) technology in the crucial area of therapeutic drug monitoring (TDM).
Dr. Phillip Morgan PhD of King’s College Hospital and the NHS Foundation Trust will present his work on the evaluation of a Volumetric Absorptive Microsampling device for tacrolimus measurement in routine drug monitoring, Wednesday 16 September, between 8:30 and 10:00 in Meeting Room B1, as part of a focus on immunosuppressants. He will explore an exciting alternative to the current protocol for tacrolimus monitoring and share the encouraging results he has achieved.
Dr. Morgan’s presentation is just one of several opportunities to learn more about microsampling at IADTMCT.
On Monday, 17 September at 16:00, Dr. Neil Spooner (Spooner Bioanalytical Solutions), Dr. Marieke G.G. Sturkenboom (University Medical Center Groningen), and Dr. Suzanne Parker (The University of Queensland, Centre for Clinical Research) will participate in a symposium specifically around issues in microsampling, including the industry-wide proliferation of dried capillary blood sampling, issues around sampling from critically ill patients, and the rise and future of patient-centered approaches to blood sampling.
On Tuesday morning, 18 September at 7:30, Dr. Sturkenboom will chair a roundtable discussion, “Hematocrit and dried blood microsampling: Still an issue?” addressing one of the most long-running topics in dried blood sampling.
The ease, convenience, and agency that microsampling technology has brought to TDM is one of the main reasons it is currently garnering so much international interest. When we set out to solve for the limitations of dried blood spot cards, we ended up forever changing the way patients relate to their medication and monitoring regimens, with the support of the clinical and scientific research community that will be present in full force at IADTMCT.